Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae009 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Megan Othus und 6 weiteren Autor:innen. Beteiligte Einrichtung: SWOG Cancer Research Network Statistical Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Background
RECIST criteria for progressive disease, partial response, and complete response, reflecting +20%, −30%, and −100% tumor size changes, respectively, are critical outcome variables in oncology clinical trials. Herein, we evaluated post-immunotherapy tumor size change correlation with outcomes.
Methods
We used a unique clinical trial data resource, a multicenter basket trial in patients with rare solid tumors treated with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) between 2017 and 2023 (National Cancer Institute/Southwest Oncology Group-sponsored DART trial [NCT02834013]) (open at 1083 sites at its peak). Outcome associations were evaluated by survival analysis techniques including Martingale residuals.
Results
In 638 evaluable patients, we found strong linear relationships between percent change in tumor measurement up to a 40%-50% increase and progression-free (PFS) and overall survival (OS) (both Cox regression P < .001; landmark analyses based on day 65). Pearson R correlation between survival estimates and tumor change category were −0.94, −0.89, and −0.89 (PFS) and −0.84, −0.90, and −0.90 (OS) for median, 6-month (PFS), and 1-year (OS) and for 1-year (PFS) and 2-year (OS) estimates.
Conclusions
Percent change in tumor measurement per RECISTv1.1 (the sum of longest dimensions of target lesions) has a linear association with PFS and OS up to a 40% to 50% increase in tumor measurement in this cohort of patients with rare cancers who received combination immune checkpoint blockade. Quantitative first scan tumor measurement changes include important information to evaluate the potential efficacy of a therapy beyond the proportion of patients who achieve an objective response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- SWOG Cancer Research Network Statistical Center, Seattle, WA, USA.
- Division of Public Health, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Medical Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.
- Department of Medicine, Northwestern University, Chicago, IL, USA.
- Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA (during conduct of trial for E Sharon).
- Department of Medicine, Dana-Farber/Harvard Cancer Center, Boston, MA, USA (current).
ORCID-Profile: Megan Othus, Howard Streicher, Razelle Kurzrock
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
- Bristol-Myers Squibb Company
Zitieren
APA
Othus, M., Patel, S. P., Chae, Y. K., Dietrich, E., Streicher, H., Sharon, E., & Kurzrock, R. (2024). Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae009
Vancouver
Othus M, Patel SP, Chae YK, Dietrich E, Streicher H, Sharon E, et al. Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae009
BibTeX
@article{Othus2024,
author = {Othus, Megan and Patel, Sandip P and Chae, Young K and Dietrich, Eliana and Streicher, Howard and Sharon, Elad and Kurzrock, Razelle},
title = {Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae009}
}
EUVIMED